Nevertheless, an adequate intake of nutrients should be a prerequisite of any treatment in order to maintain or gain muscle mass.54 In a recent study, Hulmi and coworkers proposed blocking of activin receptor type IIb (ACVR2B) ligands by administration of soluble ligand binding domain of ACVR2B (sACVR2B‐Fc) to counteract doxorubicin‐induced skeletal muscle atrophy. This evidence concerns the gene ACVR2B and muscular atrophy.